Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 1/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 17/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2617271 | 0.87 | CENPE (0.48) | CENPEMAOB | |
| SCHEMBL2617273 | 0.87 | CENPE (0.64) | CENPES1PR1S1PR3XDH | |
| SCHEMBL14531634 | 0.85 | CENPE (0.64) | CENPES1PR1S1PR3XDH | |
| SCHEMBL4534322 | 0.84 | CENPE (0.63) | CENPES1PR1S1PR3XDH | |
| SCHEMBL2104297 | 0.84 | CENPE (0.63) | CENPES1PR1S1PR3XDH | |
| SCHEMBL2104270 | 0.83 | CENPE (0.61) | CENPES1PR1S1PR3XDH | |
| SCHEMBL13644395 | 0.80 | CENPE (0.61) | CENPES1PR1S1PR3XDH | |
| SCHEMBL3462107 | 0.76 | CENPE (0.69) | CENPES1PR1S1PR3XDH | |
| SCHEMBL13161696 | 0.76 | CENPE (0.69) | CENPES1PR1S1PR3XDH | |
| SCHEMBL2631399 | 0.76 | CENPE (0.47) | CENPES1PR1S1PR3XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 54/4885S1PR1 2943/4885S1PR3 2814/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 50/4885S1PR1 2584/4885S1PR3 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.